Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Creative Life Science CoROCO:7837 28 EV-to-EBITDA is 7.47 as of Sep. 21, 2026, which is 32% below its 10-year median of 10.92. GuruFocus rates ROCO:7837 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 430 Biotechnology companies, Creative Life Science Co ranks better than 62.09% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Creative Life Science Co's enterprise value is NT$1,943 Mil.
Creative Life Science Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$260 Mil. Therefore, Creative Life Science Co's EV-to-EBITDA for today is 7.47.
The historical rank and industry rank for Creative Life Science Co's EV-to-EBITDA or its related term are showing as below:
ROCO:7837'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.65 Med: 10.92 Max: 12.19
Current: 7.47
During the past 4 years, the highest EV-to-EBITDA of Creative Life Science Co was 12.19. The lowest was 6.65. And the median was 10.92.
ROCO:7837's EV-to-EBITDA is ranked better than 62.09% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs ROCO:7837: 7.47
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Creative Life Science Co (ROCO:7837) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Creative Life Science Co's PE Ratio (TTM) for today is calculated as:
Creative Life Science Co's share price for today is NT$83.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Creative Life Science Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$5.211.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Life Science Co EV-to-EBITDA Chart
Creative Life Science Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
EV-to-EBITDA
-
-
-
10.70
Creative Life Science Co Semi-Annual Data
Jun24
Jun25
Dec25
Jun26
EV-to-EBITDA
-
25.52
10.86
8.39
ROCO:7837 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Creative Life Science Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Life Science Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Creative Life Science Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Creative Life Science Co's EV-to-EBITDA falls into.
Creative Life Science Co's current Enterprise Value is NT$1,943 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Creative Life Science Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$260 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Life Science Co (ROCO:7837) has a EV-to-EBITDA of 7.47 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Creative Life Science Co. This is 32% below median its historical median of 10.92. Over the past decade, Creative Life Science Co's EV-to-EBITDA has ranged from 6.65 to 12.19. According to the industry distribution chart, Creative Life Science Co ranks #163 out of 430 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Creative Life Science Co's EV-to-EBITDA too high?
Creative Life Science Co's current EV-to-EBITDA of 7.47 is 32% below median its 10-year median of 10.92. Over the past 10 years, this metric has ranged from a low of 6.65 to a high of 12.19. The Biotechnology industry median EV-to-EBITDA is 13.02. Creative Life Science Co's value of 7.47 is 42.6% below this industry median. Based on the distribution chart, Creative Life Science Co ranks #163 out of 430 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Creative Life Science Co has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Creative Life Science Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Creative Life Science Co ranks #163 out of 430 companies for EV-to-EBITDA. This puts Creative Life Science Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.02. Creative Life Science Co's value of 7.47 is 42.6% below this benchmark. Historically, Creative Life Science Co's own EV-to-EBITDA has ranged from 6.65 to 12.19 over the past decade. While the company's 10-year median is 10.92 vs. the industry median of 13.02, Creative Life Science Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Life Science Co's current EV-to-EBITDA of 7.47 is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Creative Life Science Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Life Science Co's current EV-to-EBITDA is 7.47, which is 32% below median its own 10-year median of 10.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Life Science Co stock overvalued right now?
Creative Life Science Co (ROCO:7837) has a current EV-to-EBITDA of 7.47. The current EV-to-EBITDA is 7.47, which is 32% below median its 10-year median of 10.92 and 42.6% below the Biotechnology industry median of 13.02. Creative Life Science Co's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Creative Life Science Co (ROCO:7837), the current EV-to-EBITDA is 7.47 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Creative Life Science Co Ltd is engaged in providing products of microbiology, and it has prepared media products and diagnostic reagents. The main products of CMP (Creative Media Plate) are solid and liquid media, which can be used for clinical microbiology, basic microbial research, environmental monitoring, biosafety testing, and quality control. Its product line is Transport Medium, Prepared Tube Media, Prepared Plated Media, VTM & I-VTM, Bacterial strain preservation system, and CMP SteriPack triple wrapped media.
28GF Score
Get the complete analysis for ROCO:7837
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7837 has been successfully added to your 
